Y Intercept Hong Kong Ltd Invests $4.81 Million in Perrigo Company plc $PRGO

Y Intercept Hong Kong Ltd bought a new stake in shares of Perrigo Company plc (NYSE:PRGO) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 447,451 shares of the company’s stock, valued at approximately $4,806,000. Y Intercept Hong Kong Ltd owned 0.33% of Perrigo at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. SG Americas Securities LLC boosted its holdings in Perrigo by 1,495.6% during the fourth quarter. SG Americas Securities LLC now owns 134,433 shares of the company’s stock worth $1,871,000 after buying an additional 126,008 shares in the last quarter. Vanguard Group Inc. increased its holdings in Perrigo by 7.9% in the fourth quarter. Vanguard Group Inc. now owns 14,983,369 shares of the company’s stock valued at $208,568,000 after buying an additional 1,101,154 shares in the last quarter. Sound Income Strategies LLC raised its position in shares of Perrigo by 58.6% in the fourth quarter. Sound Income Strategies LLC now owns 1,138,357 shares of the company’s stock worth $17,110,000 after acquiring an additional 420,626 shares during the period. BW Gestao de Investimentos Ltda. raised its position in shares of Perrigo by 7.7% in the third quarter. BW Gestao de Investimentos Ltda. now owns 1,582,119 shares of the company’s stock worth $35,234,000 after acquiring an additional 112,595 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Perrigo by 2.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 7,695,238 shares of the company’s stock worth $171,367,000 after acquiring an additional 181,828 shares in the last quarter. 95.91% of the stock is owned by hedge funds and other institutional investors.

Perrigo Stock Down 0.1%

Shares of NYSE PRGO opened at $11.01 on Monday. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of -0.84, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51. The company’s 50-day simple moving average is $10.89 and its 200-day simple moving average is $12.11. The company has a quick ratio of 1.59, a current ratio of 2.72 and a debt-to-equity ratio of 1.45. Perrigo Company plc has a 52-week low of $9.23 and a 52-week high of $28.43.

Perrigo (NYSE:PRGO) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. Perrigo had a negative net margin of 43.50% and a positive return on equity of 9.96%. The firm had revenue of $841.80 million for the quarter, compared to analyst estimates of $1.04 billion. During the same period last year, the company posted $0.60 EPS. Perrigo’s quarterly revenue was down 7.2% compared to the same quarter last year. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Equities analysts predict that Perrigo Company plc will post 2.11 EPS for the current fiscal year.

Perrigo Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 16th. Stockholders of record on Friday, May 29th were given a $0.29 dividend. This represents a $1.16 annualized dividend and a dividend yield of 10.5%. The ex-dividend date was Friday, May 29th. Perrigo’s dividend payout ratio (DPR) is -8.85%.

Analyst Ratings Changes

A number of research firms have recently commented on PRGO. Weiss Ratings upgraded Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. Zacks Research raised Perrigo from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. One equities research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Perrigo presently has a consensus rating of “Hold” and an average target price of $19.33.

Perrigo Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.